Immunomedics, Inc,, 300 The American Road, Morris Plains, NJ 07950, USA.
EJNMMI Res. 2013 May 8;3(1):36. doi: 10.1186/2191-219X-3-36.
Targeted agents are increasingly used for treating cancer and other diseases, but patients may need to be carefully selected to maximize the potential for therapeutic benefit. One way to select patients is to bind an imaging radionuclide to a targeting agent of interest, so that its uptake in specific sites of disease can be visualized by positron-emission tomography (PET) or single-photon emission computed tomography.18F is the most commonly used radionuclide for PET imaging. Its half-life of approximately 2 h is suited for same-day imaging of many compounds that clear quickly from the body to allow visualization of uptake in the intended target. A significant impediment to its use, however, is the challenging coupling of 18F to a carbon atom of the targeting agent. Because fluorine binds to aluminum, we developed a procedure where the Al18F complex could be captured by a chelate, thereby greatly simplifying the way that imaging agents can be fluorinated for PET imaging. This article reviews our experience with this technology.
靶向药物越来越多地用于治疗癌症和其他疾病,但需要仔细选择患者,以最大限度地发挥治疗效果。选择患者的一种方法是将成像放射性核素与感兴趣的靶向药物结合,以便通过正电子发射断层扫描(PET)或单光子发射计算机断层扫描来可视化其在疾病特定部位的摄取。18F 是最常用于 PET 成像的放射性核素。其半衰期约为 2 小时,适合对许多从体内迅速清除的化合物进行当日成像,从而可以观察到预期靶标中的摄取。然而,其使用的一个主要障碍是将 18F 与靶向药物的碳原子进行偶联的挑战性。由于氟与铝结合,我们开发了一种方法,其中可以通过螯合物捕获 Al18F 络合物,从而大大简化了为 PET 成像氟化成像剂的方式。本文综述了我们在该技术方面的经验。